<i>N</i> -Acetylcysteine and Contrast-Induced Nephropathy in Primary Angioplasty

Abstract

Intravenous and oral N-acetylcysteine may prevent contrast-medium-induced nephropathy with a dose-dependent effect in patients treated with primary angioplasty and may improve hospital outcome. (ClinicalTrials.gov number, NCT00237614[ClinicalTrials.gov]).